9-10am PDT / 11am-1pm Colombia / 12-1pm EST / 5-6pm UK
The SCC Journal Club meets monthly the first Friday of every month. Presentations will focus on a variety of articles and perspectives related to cannabis medicine, including but not limited to clinically-relevant articles and research methodology-focused papers.
Presenters:
James Lowder, MD & Patrick Tso, PhD (bios below)
Topic:
Pharmacokinetics of Cannabinoids & the Lipid Absorption Pathway
Articles to be Discussed:
- Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy
- The Pharmacokinetics and the Pharmacodynamics of Cannabinoids
FREE for SCC members. $10 for non members.
Want to sign up to present an article? Contact us here.
Learn more about SCC membership options.
James N. Lowder, MD is a board-certified oncologist trained at Case Western Reserve University and Stanford University, formerly on the staff of the Cleveland Clinic. He has worked in development in the pharmaceutical and diagnostic industry for 30 years and is currently the Chief Medical Officer at Impact-Naturals, a company developing cannabinoid products for use
in the enhancement of life-style and personal health. Impact-Naturals aims to produce products which are designed using scientific principles throughout their journey from inception to the hands of the customer.
Patrick Tso, PhD graduated in 1978 from the University of Western Australia in Physiology working under Professor W.J. Simmonds. His thesis work was on the role of biliary lecithin on the formation and secretion of chylomicrons. He has worked extensively with the gastrointestinal tract and the lymphatic system (over 40 years), especially the absorption of lipids. He has published at length on the formation and secretion of chylomicrons and the process regulating it. He was awarded the Distinguished Research prize from the American Physiological Society for his work on apolipoprotein A-IV. Over the years, his laboratory has pioneered a number of concepts and approaches to study intestinal fat absorption. He has over 20 years on various NIH Study Sections and 4 years on the NIDDK Council, and has consulted with a number of pharmaceutical companies including: Ajinomoto of Japan, Lilly, Johnson and Johnson, Pfizer, Upjohn, Catalent, Abbott Nutrition, Merck, Sankyo. He is currently the Mary Emery Professor of Pathology.
